Gastroparesis — delayed gastric emptying — is the anchor injury in the GLP-1 mass-tort docket. As of May 2026, MDL 3094 (In Re: Glucagon-Like Peptide-1 Receptor Agonists Products Liability Litigation) before Judge Karen S. Marston in the Eastern District of Pennsylvania consolidates 3,636 cases alleging GI injuries including gastroparesis, severe vomiting, and intestinal blockage. The case count climbed from 3,363 in mid-April and 3,546 in late March, with no global settlement and no bellwether trial yet scheduled.
The mechanism is not in dispute: slowed gastric motility is one of the documented pharmacologic effects of GLP-1 receptor agonists. The legal question is the adequacy of the warning label. Expert discovery closed earlier this year; Daubert and summary judgment motions are pending.
See also [[mdl-3094]], [[naion]], and [[products-liability]]. Gastroparesis also surfaces in trial-side discontinuation rates and informs the slower dose-escalation schemes now standard in Phase 3 obesity programs.
Two federal multidistrict litigations against GLP-1 manufacturers continue to expand. MDL 3094 — In Re: Glucagon-Like Peptide-1 Receptor Agonists Products Liability Litigation — now consolidates 3,636 cases alleging gastrointestinal injury, including gastroparesis and severe vomiting. MDL 3163, created December 15, 2025 after the JPML approved consolidation of vision-loss cases tied to non-arteritic anterior ischemic optic neuropathy (NAION), holds 86 cases as of May 6. Both sit before Judge Karen S. Marston in the Eastern District of Pennsylvania; no bellwether trial has been scheduled and no global settlement is in negotiation.
The GLP-1 mass tort litigation (MDL 3094) before Judge Karen Marston in the Eastern District of Pennsylvania now includes 3,363 cases alleging gastroparesis and other injuries. Expert discovery closed in late March, with Daubert motions due April 28 and summary judgment motions due April 30. A Science Day on vision loss claims is set for June 2.
Over 3,546 lawsuits are now consolidated in two federal MDLs — one for gastroparesis and one for NAION vision loss. On March 3, a federal judge appointed lead counsel for the NAION MDL. Studies show semaglutide users face a fourfold increase in NAION risk, with vision loss claims now generating more legal attention than earlier gastroparesis cases.